Evidence map›Paper›PMID 35925904›Full record

Observational studyPloS one2022

Predictors of chronic COVID-19 symptoms in a community-based cohort of adults.

Jonathan I Silverberg, Israel Zyskind, Hiam Naiditch, Jason Zimmerman, Aaron E Glatt, Abraham Pinter, Elitza S Theel, Michael J Joyner, D Ashley Hill, Miriam R Lieberman and 4 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 1 country.

Jonathan I SilverbergDepartment of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, United States of America.ORCID 0000-0003-3686-7805
Israel ZyskindDepartment of Pediatrics, NYU Langone Medical Center, New York, NY, United States of America.ORCID 0000-0003-3422-9631
Hiam NaiditchDepartment of Medicine, Yale University School of Medicine, New Haven, CT, United States of America.
Jason ZimmermanMaimonides Medical Center, Brooklyn, NY, United States of America.
Aaron E GlattDepartment of Medicine, Mount Sinai South Nassau and the Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
Abraham PinterPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, United States of America.
Elitza S TheelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States of America.
Michael J JoynerDepartment of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, MN, United States of America.
D Ashley HillResourcePath, Sterling, VA, United States of America.ORCID 0000-0003-1067-3922
Miriam R LiebermanDepartment of Dermatology, State University of New York Downstate Medical Center, New York, NY, United States of America.
Elliot BigajerDivision of Gastroenterology, Department of Medicine, Brookdale University Hospital and Medical Center, Brooklyn, NY, United States of America.
Daniel StokMemorial Sloan Kettering Cancer Center, New York, NY, United States of America.
Elliot FrankDivision of Infectious Diseases, Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ, United States of America.ORCID 0000-0002-8342-599X
Avi Z RosenbergDepartment of Pathology, Johns Hopkins University, Baltimore, MD, United States of America.
Maimonides Medical Center · USMayo Clinic · USBrookdale University Hospital and Medical Center · USGeorge Washington University · USHackensack Meridian Health · USIcahn School of Medicine at Mount Sinai · USJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USRutgers, The State University of New Jersey · USState University of New York · USYale University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Variant Hemoglobin and Cardiorespiratory Regulation in HumansR35HL139854 · NHLBI · MAYO CLINIC ROCHESTER · PI JOYNER, MICHAEL J · 2018 to 2024
$5.8M
NCI NIH HHS P30 CA008748NHLBI NIH HHS R35 HL139854
6 · The paper itself

Abstract

backgroundCOVID-19 can cause some individuals to experience chronic symptoms. Rates and predictors of chronic COVID-19 symptoms are not fully elucidated.

objectiveTo examine occurrence and patterns of post-acute sequelae of SARS-CoV2 infection (PASC) symptomatology and their relationship with demographics, acute COVID-19 symptoms and anti-SARS-CoV-2 IgG antibody responses.

methodsA multi-stage observational study was performed of adults (≥18 years) from 5 US states. Participants completed two rounds of electronic surveys (May-July 2020; April-May 2021) and underwent testing to anti-SARS-CoV-2 nucleocapsid protein IgG antibody testing. Latent Class Analysis was used to identify clusters of chronic COVID-19 symptoms.

resultsOverall, 390 adults (median [25%ile, 75%ile] age: 42 [31, 54] years) with positive SARS-CoV-2 antibodies completed the follow-up survey; 92 (24.7%) had ≥1 chronic COVID-19 symptom, with 11-month median duration of persistent symptoms (range: 1-12 months). The most common chronic COVID-19 symptoms were fatigue (11.3%), change in smell (9.5%) or taste (5.6%), muscle or joint aches (5.4%) and weakness (4.6%). There were significantly higher proportions of ≥1 persistent COVID-19 symptom (31.5% vs. 18.6%; Chi-square, P = 0.004), and particularly fatigue (15.8% vs. 7.3%, P = 0.008) and headaches (5.4% vs. 1.0%, P = 0.011) in females compared to males. Chronic COVID-19 symptoms were also increased in individuals with ≥6 acute COVID-19 symptoms, Latent class analysis revealed 4 classes of symptoms. Latent class-1 (change of smell and taste) was associated with lower anti-SARS-CoV-2 antibody levels; class-2 and 3 (multiple chronic symptoms) were associated with higher anti-SARS-CoV-2 antibody levels and more severe acute COVID-19 infection. LIMITATIONS: Ambulatory cohort with less severe acute disease.

conclusionIndividuals with SARS-CoV-2 infection commonly experience chronic symptoms, most commonly fatigue, changes in smell or taste and muscle/joint aches. Female sex, severity of acute COVID-19 infection, and higher anti-SARS-CoV-2 IgG levels were associated with the highest risk of having chronic COVID-19 symptoms.

Indexed as

COVID-19AdultAntibodies, ViralFatigueFemaleHumansImmunoglobulin GMalePainRNA, ViralSARS-CoV-2Antibodies, ViralImmunoglobulin GRNA, Viral

Identifiers

PMID35925904
PMCPMC9352033
OpenAlexW4289782676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.